๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 26 Guangzhou 23 Shanghai 15 Hangzhou 13 Wuhan 13
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing26 Guangzhou23 Shanghai15 Hangzhou13 Wuhan13
All 57 locations
Target enrolment
to

Trials with a site in Hangzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
Takeda
Phase 2
36
Beijing, Guangdong, Nanning, Wuhan, Xi'an, Jinan, Chengdu, Hangzhou
2026-09-01
Recruiting
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
NCT07319832Short Bowel Syndrome (SBS)
Takeda
Observational
12
Guangzhou, Shanghai, Hangzhou
2026-03-05
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
Takeda
Phase 2
90
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2026-01-26
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
Takeda
Phase 2
200
Wuhan, Xi'an, Shanghai, Kunming, Hangzhou
2025-11-03
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440Fabry Disease
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320Crohn's Disease (CD)
Takeda
Phase 3
120
Beijing, Zhengzhou, Shanghai, Hangzhou
2022-02-10
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
Beijing, Zhengzhou, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-10
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
Takeda
Phase 1/2
334
Beijing, Wuhan, Shanghai, Hangzhou
2016-06-16
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 13 studies
PhaseStudiesRecruitingShare
Phase 25238.5%
Phase 35338.5%
Observational2215.4%
Phase 1/2107.7%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Takeda137
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.